---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic burden and healthcare resource utilization"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: Economic burden and healthcare resource utilization. Topics: Cost of illness in the United Kingdom, 2007 survey; Targeted review of economic evidence across Niemann-Pick disease types; Medication use in the International Niemann-Pick Disease Registry; Prescription adjudication and rejection rates for approved Niemann-Pick disease type C therapies. 4 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description/economic-burden-and-healthcare-resource-utilization"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic burden and healthcare resource utilization

<a id="heading-2.2.1.8.2"></a>

## 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

### Cost of illness in the United Kingdom, 2007 survey

> “In total, 18 Medical Resource Use questionnaires (29% response rate) were received and analysed.”
> “The mean total annual cost (SD) of NP-C per patient was 39,168 pounds (50,315 pounds); 46% were direct medical costs, to which home visits and residential care contributed 68% and 15%, respectively.”
> “If only direct medical costs were considered, the mean annual cost (SD) per patient was reduced to 18,012 pounds (46,536 pounds).”
> “The direct annual per-patient cost of NP-C illness in 2007 appears moderate when compared with other rare and severely disabling diseases.”
> “However, cost estimates may be conservative, since findings are limited by a small sample size, low survey response rate and potential recall bias.”

Source: [Imrie et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19725798/)

<a id="topic-2.2.1.8.2-2"></a>

### Targeted review of economic evidence across Niemann-Pick disease types

> “Niemann-Pick disease (NPD) is a rare, progressive disorder associated with substantial socioeconomic burden.”
> “Nine studies (2012-2026) from Canada, Portugal, the US, Brazil, the UK, and multinational settings were included.”
> “A Portuguese study reported substantial direct healthcare costs associated with management of NPD.”
> “In the US, 70.0% of patients were aged < 18 years, with respiratory disorders accounting for most hospitalizations and emergency visits.”
> “In Brazil, hospitalizations increased from 33.3% at diagnosis to 45.9% during follow-up.”

Source: [Sharma et al. (2026)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-europe-2026/poster-session-3-4/economic-perspectives-on-niemann-pick-disease-a-targeted-review-of-economic-evidence)

<a id="topic-2.2.1.8.2-3"></a>

### Medication use in the International Niemann-Pick Disease Registry

> “Miglustat use was recorded in 62.4% of patients and the most common symptomatic therapies used by patients were antiepileptics (32.9%), antidepressants (11.8%) and antacids (9.4%).”

Source: [Bolton et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8842861/)

<a id="topic-2.2.1.8.2-4"></a>

### Prescription adjudication and rejection rates for approved Niemann-Pick disease type C therapies

> “Prescription adjudication data showed low fill rates within 30 days for these drugs among all payers (Figure 4.8).”
> “For Aqneursa, both commercial payers and Medicaid rejected approximately 80% of prescriptions.”
> “For Miplyffa, 55%-65% of prescriptions were rejected by commercial payers and Medicaid.”
> “Thus, lengthy delays due to the prior authorization process may contribute to the high rejection rate, as very few prescriptions for either Aqneursa or Miplyffa were filled on the first attempt.”

Source: [ICER Launch Price and Access Report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_2026_Launch-Price-and-Access-Final-Report_ForPublication-1.pdf)

<a id="topic-2.2.1.8.2-5"></a>

### U.S. claims-based cost and resource use study of Niemann-Pick disease type C

No evidence found.

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
